전사체학 시장 : 세계 산업 규모, 점유율, 동향, 기회, 예측 - 컴포넌트별, 기술별, 용도별, 최종사용자별, 지역별 부문, 경쟁(2020-2030년)
Transcriptomics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Component, By Technology, By Application, By End User, By Region and Competition, 2020-2030F
상품코드:1796840
리서치사:TechSci Research
발행일:2025년 08월
페이지 정보:영문 185 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
전사체학 세계 시장 규모는 2024년에 75억 3,000만 달러로 평가되었습니다. 예측 기간 중 연평균 복합 성장률(CAGR)은 5.33%를 나타낼 전망이며, 2030년에는 102억 8,000만 달러에 이를 것으로 예측됩니다.
개발도상국의 유전성 질환 진단을 위한 RNA 시퀀싱과 NGS의 적용 확대로 인해 전 세계 트랜스스크립믹스 시장은 괄목할 만한 성장세를 보이고 있습니다. 또한, 새로운 마이크로어레이 기술의 도입으로 신기술 개발을 위한 정부 기관의 이니셔티브와 투자 증가로 인해 전 세계 여러 지역에서 트랜스스크립틱스에 대한 수요가 크게 증가하고 있습니다. 또한, 새로운 기술의 채택이 증가하고 치료를 위한 개인 맞춤형 의료에 대한 수요가 증가하는 것도 트랜스스크립틱스 수요를 증가시켜 시장 성장을 가속할 것으로 예측됩니다.
시장 개요
예측 기간
2026-2030년
시장 규모 : 2024년
75억 3,000만 달러
시장 규모 : 2030년
102억 8,000만 달러
CAGR : 2025년-2030년
5.33%
급성장 부문
차세대 시퀀싱
최대 시장
북미
또한, 바이오 제약 기업 증가와 연구개발에 대한 지출 증가는 트랜스크립틱스 수요를 더욱 증가시켜 시장 성장을 뒷받침할 것으로 예측됩니다. 미국에서는 매년 4명 중 1명꼴로 선천적 결함을 가진 아기가 태어나고 있으며, 매년 미국에서 태어나는 아기 33명 중 1명이 선천적 결함의 영향을 받고 있습니다. 이는 약 12만 명의 아기에 해당합니다. 트랜스크립믹스는 유전체에서 생산되는 RNA 전사체의 완전한 집합인 트랜스크립톰을 연구하는 학문입니다.
용도별(Drug Discovery & Development, 세포생물학, 단세포 해석, 유전자 발현, 기타)
최종사용자별(바이오테크놀러지 및 제약 기업, 학술기관 및 연구기관, 기타)
지역별
기업별(2024년)
시장 맵
컴포넌트별
기술별
용도별
최종사용자별
지역별
제7장 북미의 전사체학 시장 전망
시장 규모와 예측
시장 점유율과 예측
북미 : 국가별 분석
미국
캐나다
멕시코
제8장 유럽의 전사체학 시장 전망
시장 규모와 예측
시장 점유율과 예측
유럽 : 국가별 분석
프랑스
독일
영국
이탈리아
스페인
제9장 아시아태평양의 전사체학 시장 전망
시장 규모와 예측
시장 점유율과 예측
아시아태평양 : 국가별 분석
중국
인도
일본
한국
호주
제10장 남미 전사체학 시장 전망
시장 규모와 예측
시장 점유율과 예측
남미 : 국가별 분석
브라질
아르헨티나
콜롬비아
제11장 중동 및 아프리카 전사체학 시장 전망
시장 규모와 예측
시장 점유율과 예측
중동 및 아프리카 : 국가별 분석
남아프리카공화국
사우디아라비아
아랍에미리트(UAE)
제12장 시장 역학
성장 촉진요인
과제
제13장 시장 동향과 발전
최근 동향
인수합병(M&A)
제품 출시
제14장 Porter의 Five Forces 분석
업계내 경쟁
신규 참여 가능성
공급업체의 힘
고객의 힘
대체품의 위협/서비스
제15장 SWOT 분석 : 세계의 전사체학 시장
제16장 경쟁 구도
Agilent Technologies, Inc.
ANGLE plc.
Bio-Rad Laboratories, Inc.
Becton, Dickinson, and Company
Fluidigm Corporation
BioSypder, Inc.
Danaher Corporation
10x Genomics, Inc.
Pacific Biosciences of California, Inc.
NanoString Technologies, Inc.
제17장 전략적 제안
제18장 회사 소개 및 면책조항
LSH
영문 목차
영문목차
Global Transcriptomics Market was valued at USD 7.53 billion in 2024 and is expected to reach USD 10.28 billion by 2030 with a CAGR of 5.33% during the forecast period. The global market for Transcriptomics is experiencing significant growth, driven by the growing application of RNA sequencing and NGS for the diagnosis of genetic illness in the developing countries. Additionally, growing initiative and investments by government organizations for developing new technology, with the introduction of new microarray technology have significantly increased the demand for transcriptomics across different parts of the globe. Additionally, the rising adoption of new technology and growing demand for personalized medicine for treatments are further expected to increase the demand for transcriptomics, thereby fuelling the market growth.
Market Overview
Forecast Period
2026-2030
Market Size 2024
USD 7.53 Billion
Market Size 2030
USD 10.28 Billion
CAGR 2025-2030
5.33%
Fastest Growing Segment
Next Generation Sequencing
Largest Market
North America
Furthermore, increasing number of biopharmaceutical companies and growing expenditure on research and development are further expected to increase the demand for transcriptomics, thereby supporting the market growth. Every 4 1/2 minutes, a baby is born with a birth defect in United States every year and affects 1 in every 33 babies born in the United States each year. That translates into about 120,000 babies. Transcriptomics is the study of the transcriptome, which is the complete set of RNA transcripts that are produced by the genome.
Key Market Drivers
Advancements in High-Throughput Sequencing Technologies
The rapid evolution and increased affordability of high-throughput sequencing technologies-particularly RNA sequencing (RNA-seq)-have significantly propelled the growth of the global transcriptomics market. RNA-seq enables the precise quantification of transcripts and discovery of novel RNA species across various sample types, thereby facilitating large-scale gene expression profiling in both basic research and clinical applications. Governments across the globe are investing heavily in next-generation sequencing (NGS) infrastructure. For instance, the U.S. National Institutes of Health (NIH) allocated over $1.5 billion in 2023 for initiatives linked to genomic medicine, including transcriptomics. NIH's All of Us Research Program has specifically emphasized the inclusion of RNA expression data to understand disease biology across diverse populations.
In addition, transcriptomics technologies are increasingly integrated into disease biomarker discovery, drug development pipelines, and personalized medicine. Projects such as the Genotype-Tissue Expression (GTEx) Project by the NIH have generated comprehensive gene expression datasets, enabling researchers to map tissue-specific gene expressions and variation across populations. The plummeting costs of RNA-seq-from over $1,000 per sample a decade ago to less than $100 today-have democratized access to these technologies. This price drop is particularly impactful for academic institutions and biotech companies in developing nations, driving adoption at a global scale. Moreover, automation in sample preparation, data analysis, and bioinformatics pipelines further accelerates throughput and reduces labor costs, enhancing scalability.
Key Market Challenges
Complex Data Interpretation and Bioinformatics Bottlenecks
Despite the advances in transcriptomic technologies, data complexity and bioinformatics limitations remain substantial challenges hindering market growth. Transcriptomic analyses-especially using RNA-seq-generate enormous volumes of data, often reaching hundreds of gigabytes per sample. Extracting meaningful insights from these datasets requires sophisticated algorithms, powerful computational infrastructure, and expertise in bioinformatics. The European Bioinformatics Institute (EMBL-EBI) and NIH's National Center for Biotechnology Information (NCBI) host large-scale transcriptomic repositories such as GEO (Gene Expression Omnibus) and ArrayExpress. However, interpreting this data requires integration with proteomics, genomics, and clinical phenotypes, which adds further layers of complexity. For many healthcare providers and small research labs, this technical requirement becomes a major barrier.
According to a 2022 survey by the Global Alliance for Genomics and Health (GA4GH), more than 60% of genomics labs identified a shortage of bioinformatics talent as a significant operational bottleneck. Furthermore, inconsistencies in data normalization, quality control, and analysis pipelines often lead to irreproducible results, limiting the translational utility of transcriptomics in clinical settings. Another related challenge is the need for standardized bioinformatics workflows. While initiatives such as the FDA's SEQC (Sequencing Quality Control) Project aim to establish quality benchmarks, globally accepted standards for transcriptomic data interpretation are still evolving. Until data analysis becomes more user-friendly and standardized across platforms, the complexity of transcriptomic datasets will continue to restrain broader adoption in clinical and research domains.
Key Market Trends
Integration of Multi-Omics Approaches in Disease Research
A growing trend in transcriptomics is its integration with other omics technologies, including genomics, proteomics, epigenomics, and metabolomics, to provide a holistic view of biological systems. This multi-omics approach enhances the understanding of complex disease mechanisms by correlating gene expression profiles with protein activity, epigenetic modifications, and metabolic changes. The U.S. National Cancer Institute (NCI) has launched several multi-omics initiatives, including the Human Tumor Atlas Network (HTAN), which maps tumors using transcriptomics, genomics, and imaging. The goal is to understand how tumors evolve over time and how patients respond to therapy, enabling the development of personalized treatment plans.
Similarly, the UK Biobank, backed by the UK government and Wellcome Trust, is increasingly adding transcriptomic data to its already vast genomic and clinical dataset. This allows researchers to connect gene expression patterns with real-world disease outcomes in a population-scale setting. This trend is not limited to developed countries. India's GenomeIndia project, supported by the Department of Biotechnology, is also moving towards the integration of transcriptomics with proteomic and metabolomic data to understand ethnic-specific disease vulnerabilities. Such integrative research helps in discovering novel drug targets, stratifying patients for clinical trials, and predicting disease progression. With advancements in artificial intelligence (AI) and machine learning (ML), multi-omics data integration is becoming more feasible, driving deeper biological insights and fueling demand for transcriptomic technologies.
Key Market Players
Agilent Technologies, Inc.
ANGLE plc.
Bio-Rad Laboratories, Inc.
Becton, Dickinson, and Company
Fluidigm Corporation
BioSypder, Inc.
Danaher Corporation
10x Genomics, Inc.
Pacific Biosciences of California, Inc.
NanoString Technologies, Inc.
Report Scope:
In this report, the Global Transcriptomics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Transcriptomics Market, By Component:
Instruments
Consumables
Software & Services
Transcriptomics Market, By Technology:
Next Generation Sequencing
Polymerase Chain Reaction
Microarray
In-Situ Hybridization
Others
Transcriptomics Market, By Application:
Drug Discovery & Development
Cell Biology
Single Cell Analysis
Gene Expression
Others
Transcriptomics Market, By End User:
Biotechnology & Pharmaceutical Companies
Academic & Research Institutions
Others
Transcriptomics Market, By Region:
North America
United States
Mexico
Canada
Europe
France
Germany
United Kingdom
Italy
Spain
Asia-Pacific
China
India
South Korea
Japan
Australia
South America
Brazil
Argentina
Colombia
Middle East and Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies presents in the Global Transcriptomics Market.
Available Customizations:
Global Transcriptomics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Clinical Trial Analysis
5.1. Ongoing Clinical Trials
5.2. Completed Clinical Trials
5.3. Terminated Clinical Trials
5.4. Breakdown of Pipeline, By Development Phase
5.5. Breakdown of Pipeline, By Status
5.6. Breakdown of Pipeline, By Study Type
5.7. Breakdown of Pipeline, By Region
5.8. Clinical Trials Heat Map
6. Global Transcriptomics Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Component (Instruments, Consumables, Software & Services)
